TP53 and colorectal carcinoma: In the context of HSP90 inhibition, we show here that dual pathway inhibition via p53 activation by RG-7388 (Idasanutlin, a clinically relevant p53 activator) prevents upregulation of HSF1 target gene expression in human CRC cells.